Nautilus Posts First Revenue but Indefinitely Delays Broadscale Assay
NAUT sits 94% above its 52-week low of $0.62 on elevated volume (3.0× avg).
Summary
Nautilus Biotechnology posted its first revenue in Q2 2026 but indefinitely delayed its broadscale assay, pushing the commercial launch to early 2027. Cash of $84M provides runway, but the delay is a setback for the core platform.
Key Events · Earnings and Guidance · NAUT
-
First Revenue Achieved
Nautilus reported $190K in total revenue for Q2 2026, consisting of $180K from a Michael J. Fox Foundation grant and $10K from early access services. This marks the company's first revenue since inception.
-
Broadscale Assay Delayed Indefinitely
The company announced that its broadscale assay development has not advanced sufficiently to support a 2027 launch. Resources are being reallocated to accelerate proteoform applications, and the broadscale timeline is now indefinite.
-
Commercial Launch Pushed to Early 2027
Nautilus now expects to open the Voyager platform for pre-orders in early 2027, with instrument shipments beginning in mid-2027. This is a delay from prior expectations.
-
Cash Runway of at Least 12 Months
As of June 30, 2026, Nautilus held $84.0M in cash, cash equivalents, and short-term investments. Management believes this is sufficient to fund operations for at least the next 12 months.
Analysis · NAUT · Industrial Applications And Services
Nautilus achieved its first-ever revenue of $190K in Q2 2026, driven by a Michael J. Fox Foundation grant and early access services. However, the company indefinitely delayed its broadscale assay — the core long-term value driver — and pushed the commercial launch to early 2027. Cash of $84M provides runway for at least 12 months, but the delay raises questions about the platform's readiness and the timeline to meaningful revenue. The net loss narrowed to $14.5M from $15.0M a year ago, reflecting cost cuts, but the strategic pivot to proteoforms signals that the broadscale vision is further off than previously communicated.
At the time of this filing, NAUT was trading at $1.20 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $152.5M. The 52-week trading range was $0.62 to $4.31. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.